Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
Détails
ID Serval
serval:BIB_5E884C0CA0D9
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
Périodique
Archives of Disease In Childhood
Collaborateur⸱rice⸱s
Pediatric Infectious Disease Group of Switzerland (PIGS), Swiss Mother, Child HIV Cohort Study (MoCHiV)
Contributeur⸱rice⸱s
Aebi C., Bär W., Berger Ch., Besson F., Bühlmann U., Cheseaux JJ., Desgrandchamps D., Diana A., Duppenthaler A., Gervaix A., Gnehm HP., Heininger U., Hunziker UA., Kahlert C., Kind C., Kuchler H., Loher A., Masserey-Spicher V., Myers C., Nadal D., Posfay-Barbe C., Rudin C., Schaad UB., Siegrist CA., Stähelin J., Vaudaux B., Wyler-Lazarevic CA., Zingg W., Aebi C., Battegay M., Bernasconi E., Böni J., Brazzola P., Bucher HC., Bürgisser P., Calmy A., Cattacin S., Cavassini M., Cheseaux JJ., Drack G., Dubs R., Egger M., Elzi L., Fischer M., Flepp M., Fontana A., Francioli P., Furrer HJ., Fux C., Gayet-Ageron A., Gerber S., Gorgievski M., Günthard H., Gyr T., Hirsch H., Hirschel B., Hösli I., Hüsler M., Kaiser L., Kahlert Ch., Karrer U., Kind C., Klimkait T., Ledergerber B., Martinetti G., Martinez B., Müller N., Nadal D., Paccaud F., Pantaleo G., Raio L., Rauch A., Regenass S., Rickenbach M., Rudin C., Schmid P., Schultze D., Schüpbach J., Speck R., Taffé P., Telenti A., Trkola A., Vernazza P., Weber R., Wyler CA., Yerly S.
ISSN
1468-2044 (Electronic)
ISSN-L
0003-9888
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
95
Numéro
6
Pages
478-481
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children.
METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included.
RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children.
CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.
METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included.
RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children.
CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.
Mots-clé
Adolescent, CD4 Lymphocyte Count, Child, Child, Preschool, Drug Therapy, Combination, Female, Follow-Up Studies, HIV Infections/drug therapy, HIV Infections/immunology, HIV Protease Inhibitors/adverse effects, HIV Protease Inhibitors/therapeutic use, HIV-1/isolation & purification, Humans, Lopinavir, Male, Prospective Studies, Pyrimidinones/adverse effects, Pyrimidinones/therapeutic use, Ritonavir/adverse effects, Ritonavir/therapeutic use, Treatment Outcome, Viral Load
Pubmed
Web of science
Création de la notice
29/12/2010 17:46
Dernière modification de la notice
20/08/2019 15:16
Données d'usage
